ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of ProQR Therapeutics N.V. (NASDAQ:PRQR) have received a consensus rating of “Moderate Buy” from the six analysts that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $7.3333.

A number of research analysts have weighed in on the stock. Citigroup reaffirmed a “market outperform” rating on shares of ProQR Therapeutics in a research note on Wednesday, May 27th. Weiss Ratings downgraded shares of ProQR Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, June 23rd. Chardan Capital dropped their price objective on shares of ProQR Therapeutics from $4.00 to $3.00 and set a “buy” rating on the stock in a report on Friday, June 26th. Wall Street Zen cut shares of ProQR Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Saturday, May 16th. Finally, JonesTrading reduced their target price on shares of ProQR Therapeutics from $11.00 to $10.00 and set a “buy” rating for the company in a research note on Friday, June 26th.

ProQR Therapeutics Price Performance

NASDAQ PRQR opened at $1.81 on Tuesday. ProQR Therapeutics has a one year low of $1.33 and a one year high of $3.10. The firm has a market cap of $190.70 million, a P/E ratio of -3.62 and a beta of 0.07. The stock’s 50-day moving average is $1.71 and its 200-day moving average is $1.65.

ProQR Therapeutics (NASDAQ:PRQR) last issued its quarterly earnings data on Tuesday, May 12th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.15). ProQR Therapeutics had a negative return on equity of 84.87% and a negative net margin of 331.33%.The business had revenue of $2.35 million during the quarter, compared to analyst estimates of $5.19 million. Equities analysts anticipate that ProQR Therapeutics will post -0.52 EPS for the current year.

Insider Activity

In other news, Director Bart Filius purchased 150,000 shares of the company’s stock in a transaction on Friday, July 17th. The shares were purchased at an average price of $1.72 per share, with a total value of $258,000.00. Following the purchase, the director directly owned 300,000 shares of the company’s stock, valued at $516,000. This trade represents a 100.00% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Boer Daniel Anton De acquired 150,000 shares of ProQR Therapeutics stock in a transaction dated Thursday, July 9th. The shares were purchased at an average cost of $1.74 per share, with a total value of $261,000.00. Following the completion of the transaction, the chief executive officer directly owned 300,000 shares of the company’s stock, valued at $522,000. This trade represents a 100.00% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders acquired a total of 600,000 shares of company stock worth $988,500 in the last three months. Company insiders own 8.40% of the company’s stock.

Hedge Funds Weigh In On ProQR Therapeutics

Large investors have recently bought and sold shares of the company. Osaic Holdings Inc. grew its holdings in shares of ProQR Therapeutics by 59.6% in the 2nd quarter. Osaic Holdings Inc. now owns 12,050 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 4,500 shares in the last quarter. Persistent Asset Partners Ltd raised its holdings in ProQR Therapeutics by 24.5% during the fourth quarter. Persistent Asset Partners Ltd now owns 45,154 shares of the biopharmaceutical company’s stock worth $91,000 after acquiring an additional 8,874 shares in the last quarter. Diadema Partners LP raised its holdings in ProQR Therapeutics by 6.2% during the fourth quarter. Diadema Partners LP now owns 167,532 shares of the biopharmaceutical company’s stock worth $338,000 after acquiring an additional 9,838 shares in the last quarter. Bank of America Corp DE boosted its position in ProQR Therapeutics by 6.4% during the first quarter. Bank of America Corp DE now owns 185,110 shares of the biopharmaceutical company’s stock valued at $300,000 after purchasing an additional 11,186 shares during the last quarter. Finally, Raymond James Financial Inc. boosted its position in ProQR Therapeutics by 15.2% during the third quarter. Raymond James Financial Inc. now owns 110,270 shares of the biopharmaceutical company’s stock valued at $235,000 after purchasing an additional 14,549 shares during the last quarter. Institutional investors and hedge funds own 32.65% of the company’s stock.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.